More than one injection of Elonva within one treatment cycle or too high a dose of Elonva and/or (rec)FSH may increase the risk of OHSS. After administration of Elonva, no additional FSH containing product should be administered prior to stimulation day 8, as this may also increase the risk of OHSS. (See OHSS in Precautions).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
